Press release
According to Latest Report on mRNA Vaccine Market to Grow with an Impressive CAGR by 2025 | Analysis by Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics
mRNA Vaccine Market
Global mRNA Vaccine Market Overview:
The Global mRNA Vaccine Market research report is the investigation arranged by investigators, which contain a point by point examination of drivers, limitations, and openings alongside their effect on the mRNA Vaccine Market development (2020 - 2025).
Major key factors driving the growth of the Global mRNA Vaccine Market are increasing adoption of mRNA vaccine owing to its higher efficiency, shorter manufacturing times, growing licensing agreements between mRNA vaccine manufacturers, and prominent vaccine developers’ to offer advanced infectious disease vaccination. Furthermore, the excellent ability of mRNA to combine multiple molecules into a single therapeutic has gained significant attention from potential investors and the pharmaceutical industry, is again contributing the market growth.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/237419 .
The Global mRNA Vaccine Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global MRNA Vaccine Market is sub-segmented into Standardization Of Cancer Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Infection Prevention mRNA Vaccine and others. On the basis of Application, the Global mRNA Vaccine Market is classified into Infectious Disease, Cancer and others.
In terms of the geographic analysis, The mRNA Vaccine Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the mRNA Vaccine Market ecosystem results in the increasing adoption of these systems in North America.
Top Healthcare Industry News:
Moderna (May 01, 2020) - Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus - Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.
Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites. Technology transfer is expected to begin in June 2020, and the companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020. Over time, the parties intend to establish additional production suites across Lonza’s worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide assuming the currently expected dose of 50 µg. The manufacturing facilities at Lonza complement Moderna’s ongoing U.S. manufacturing efforts, which continue to ramp up to prepare for the further clinical development and commercialization of mRNA-1273.
A portion of the funding for the establishment of manufacturing operations at Lonza U.S. is covered by Moderna’s contract with Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, which was announced April 16, 2020. BARDA will support late-stage clinical development programs of mRNA-1273. Lonza’s experience in scaling manufacturing of innovative medicines, including support for more than 50 commercial approvals across regulatory jurisdictions, will support Moderna for global supply.
“We are very pleased to partner with Lonza, which shares our commitment to rapidly addressing this pandemic which has created a global health crisis,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “This long-term strategic collaboration agreement will enable Moderna to accelerate, by 10-times, our manufacturing capacity for mRNA-1273 and additional products in Moderna’s large clinical portfolio. Lonza’s global presence and expertise are critical as we scale at unprecedented speed. Our common goal is to potentially enable manufacturing of up to 1 billion doses of mRNA-1273.”
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global mRNA Vaccine Market Report 2020” @ https://www.businessindustryreports.com/buy-now/237419/single .
Top Leading Key in Players Global mRNA Vaccine Market: Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.
With the presence of a large pool of participants, the Global mRNA Vaccine Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology are some of the key vendors of mRNA Vaccine across the world. These players across mRNA Vaccine Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.
Region segment: mRNA Vaccine Market report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of mRNA Vaccine in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/237419 .
Major Points in Table of Contents:
Global mRNA Vaccine Market Report 2020
1 mRNA Vaccine Product Definition
2 Global mRNA Vaccine Market Manufacturer Share and Market Overview
2.1 Global Manufacturer mRNA Vaccine Shipments
2.2 Global Manufacturer mRNA Vaccine Business Revenue
2.3 Global mRNA Vaccine Market Overview
3 Manufacturer mRNA Vaccine Business Introduction
3.1 Moderna Therapeutics mRNA Vaccine Business Introduction
3.2 CureVac mRNA Vaccine Business Introduction
3.3 Translate Bio mRNA Vaccine Business Introduction
3.4 BioNTech mRNA Vaccine Business Introduction
3.5 Sangamo Therapeutics mRNA Vaccine Business Introduction
3.6 Argos Therapeutics mRNA Vaccine Business Introduction
………………. Request free sample to get a complete Table of Content
About us
BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.
Media Contact
Business Industry Reports
Pune – India
sales@businessindustryreports.com
+19376349940
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release According to Latest Report on mRNA Vaccine Market to Grow with an Impressive CAGR by 2025 | Analysis by Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics here
News-ID: 2208084 • Views: …
More Releases from Business Industry Reports
Tetracaine Market Exhibits a Lucrative Growth Potential during 2021-2025 | Endo …
BusinessIndustryReports has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Tetracaine Market” Research Report 2021 provides an in-depth analysis of the Tetracaine with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house). The research study examines the Tetracaine on the basis of a number of criteria,…
Cyber Warfare Market Evenly Poised To Reach A Market Value of US$ By Share, Size …
Overview of Global Cyber Warfare Market:
This report provides in-depth study of “Global Cyber Warfare Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cyber Warfare Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, the Cyber Warfare is virtual conflict between state, organization, or country by the use of computer technology to disrupt activities…
Covid-19 Impact on Cranio Maxillofacial Implant Market 2021-2025: Business Growt …
Overview of Global Cranio Maxillofacial Implant Market:
This report provides in-depth study of “Global Cranio Maxillofacial Implant Market 2021” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Cranio Maxillofacial Implant Market report also provides an in-depth survey of key players in the market organization.
According to the market research study, Craniomaxillofacial Implants are medical implants used in surgeries of maxillofacial region such as, head, face, neck, oral,…
Beginning of the bloom: The Rise of the Biohacking Market 2021-2025 | Global Key …
Global Biohacking Market Synopsis:
The report covers a forecast and an analysis of the Biohacking Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Biohacking Market along with the impact they have on the demand over the forecast…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
